Resources Repository
-
GuidelinesPublication 2011HPV Vaccine Introduction in LMIC's: Guidance on the Use of Cost-Effectiveness Models
This article is a literature review of HPV vaccination models suitable for low-income and middle-income …
This article is a literature review of HPV vaccination models suitable for low-income and middle-income country use to provide information about the feasibility of using such models in a developing country setting. The authors evaluated models in terms of their capacity, requirements, limitations and comparability. Their literature review identified six HPV vaccination models suitable for low-income and middle-income country use and representative of the literature in terms of provenance and model structure. Each model was…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Clinical Care | Calibration/Validation | Infectious Diseases | Health Systems | Science/Technology | Global -
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Costing Methods | Technology Assessment | Child/Nutrition | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Food/Agriculture | Latin America & Caribbean -
ReviewPublication 2016Choosing an Epidemiological Model Structure for Economic Evaluation
This review presents a taxonomy of epidemiological model structures and applies it to the economic …
This review presents a taxonomy of epidemiological model structures and applies it to the economic evaluation of public health interventions for non-communicable diseases. Growing pressures on health services and on social care have led to a greater need for prevention of chronic diseases. In order for decision makers to make informed judgements about how to best spend finite public health resources, they must be able to quantify the anticipated costs, benefits, and opportunity costs of…
Mathematical Models | Health/Medicine | Climate/Environment | Chronic Disease/Risk | State-Transition | Dynamic Transmission | Microsimulation | Dynamic Simulation | Social Determinants | Environmental Health | Health Systems | Culture/Society -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Technology Assessment | Infectious Diseases | Child/Nutrition | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | North America -
ReviewPublication 2012Modeling Preventative Strategies Against HPV-Related Disease in Developed Countries
This review article is part of a special supplement on “Comprehensive Control of HPV Infections …
This review article is part of a special supplement on “Comprehensive Control of HPV Infections and Related Diseases.” At the time of its writing, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females had been introduced in most developed countries, supported by modeled evaluations that had almost universally found vaccination of pre-adolescent females to be cost-effective. Vaccination of pre-adolescent males had been shown to be cost-effective at a cost per vaccinated individual of ~US$400-500 if…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Social Determinants | Health Systems | Global -
ReviewPublication 2011Simulation Models of Obesity: A Review of the Literature
Simulation models combine information from a variety of sources to provide a useful tool for …
Simulation models combine information from a variety of sources to provide a useful tool for examining how the effects of obesity unfold over time and impact population health. They can aid in the understanding of the complex interaction of the drivers of diet and activity and their relation to health outcomes. This paper provided an overview of different types of simulation models used to evaluate the potential impact of policies to address the obesity epidemic.…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | State-Transition | Microsimulation | Calibration/Validation | Decision Analysis | Child/Nutrition | Economics/Finance | Food/Agriculture -
ReviewPublication 2006Public Health Policy for Cervical Cancer Prevention: Decision Science, Economic Evaluation, & Mathematical Modeling
Several factors are changing the landscape of cervical cancer control, including a better understanding of …
Several factors are changing the landscape of cervical cancer control, including a better understanding of the natural history of human papillomavirus (HPV), reliable assays for detecting high-risk HPV infections, and a soon to be available HPV-16/18 vaccine. There are important differences in the relevant policy questions for different settings. By synthesizing and integrating the best available data, the use of modeling in a decision analytic framework can identify those factors most likely to influence outcomes,…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Decision Analysis | Infectious Diseases | Economics/Finance | Science/Technology | Global -
ReviewPublication 2003Public Health Policy and Cost-Effectiveness Analysis
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to …
This chapter presents an overview of the uses for cost-effectiveness analysis and disease-simulation modeling to rigorously evaluate alternatives to reduce mortality from cervical cancer. Scientific advances have provided opportunities over time to revisit strategies for cervical cancer prevention. How to invest health resources wisely, such that public health benefits are maximized-and opportunity costs are minimized-is a critical question in the setting of enhanced cytologic screening methods, human papillomavirus DNA testing, and vaccine development. Developing sound…
Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | Infectious Diseases | Health Systems | Policy/Regulation | Global -
ReviewPublication 2024Cost-Effectiveness of Newer Pharmacologic Treatments in Adults with Type 2 Diabetes: Systematic Review of Cost-Effectiveness Studies for the American College of Physicians
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in …
This systematic review examines the cost-effectiveness of newer antidiabetes medications for type 2 diabetes in the United States. The study screened nonindustry-funded cost-effectiveness analyses (CEAs) conducted from 2010 to 2023, focusing on estimating cost per quality-adjusted life-year (QALY) gained. Nine CEAs met the criteria, evaluating medications such as glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), and sodium–glucose cotransporter-2 inhibitors (SGLT2i), among others. Comparisons were made against metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and…
Cost-Effectiveness Analysis | Health/Medicine | Chronic Disease/Risk | North America